GERD (Gastroesophageal Reflux Disease)

Gastroenterology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Cinclus Pharma
Cinclus PharmaSweden - Stockholm
2 programs
2
Linaprazan glurate - High dosePhase 31 trial
Linaprazan glurate 50 mg Twice DailyPhase 31 trial
Active Trials
NCT07313774Not Yet Recruiting1,050Est. Dec 2028
NCT07037875Not Yet Recruiting500Est. Sep 2026

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
Cinclus PharmaLinaprazan glurate - High dose
Cinclus PharmaLinaprazan glurate 50 mg Twice Daily

Clinical Trials (2)

Total enrollment: 1,550 patients across 2 trials

NCT07313774Cinclus PharmaLinaprazan glurate - High dose

A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)

Start: Mar 2026Est. completion: Dec 20281,050 patients
Phase 3Not Yet Recruiting
NCT07037875Cinclus PharmaLinaprazan glurate 50 mg Twice Daily

A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)

Start: Sep 2025Est. completion: Sep 2026500 patients
Phase 3Not Yet Recruiting

Related Jobs in Gastroenterology

Specialty Representative, Gastroenterology – Minneapolis, Minnesota

AbbVie
Remote
11h ago

Head of Drug Product Development

Ironwood Pharmaceuticals
Boston, Massachusetts, United States
12h ago
$246K - $287K/yr

Regulatory Affairs Associate

Ferring Pharmaceuticals
Istanbul, Turkey
Yesterday

Key Account Director, Diagnostics and Research

Tempus
Remote
Yesterday
$150K - $200K/yr

QA Operation Platform Lead

Johnson & Johnson
Yokneam, Haifa District, Israel
Yesterday

Value Architecture & Engineering Lead

Johnson & Johnson
Titusville, New Jersey, United States of America
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space

Related Indications

Hepatic Impairment(79)Gastroesophageal Reflux Disease(37)Irritable Bowel Syndrome(29)Gastroesophageal Reflux(27)Liver Transplantation(24)Celiac Disease(23)Hepatic Insufficiency(22)Liver Cirrhosis(22)Gastroesophageal Reflux Disease (GERD)(14)Hepatic Encephalopathy(12)